Skip to Content
Merck
All Photos(2)

Key Documents

850103P

Avanti

17:1 Lyso PI

1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

Synonym(s):

PI(17:1(10Z)/0:0); 110718

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C26H52NO12P
CAS Number:
Molecular Weight:
601.66
UNSPSC Code:
51191904
NACRES:
NA.25

Assay

>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)

form

powder

packaging

pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))

manufacturer/tradename

Avanti Research - A Croda Brand 850103P

lipid type

phosphoglycerides

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]

General description

Lysophosphatidylinositol (LPI), a degradation product of phosphatidylinositol (PI) is a lysophospholipid subspecies, which carries inositol in its head group.

Application

17:1 Lyso PI (1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol)) has been used as an internal standard in LC-MS of mice brain lipidomic analysis. It may be used as internal standard in for the analysis of lysophosphatidylinositols (LPIs) in mice using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS) and in the quantification of lysoPI (LPI) in livers of chronic high-fat diet (HFD)-fed WT and KO mice using liquid chromatography with tandem mass spectrometry (LC-MS-MS) system.

Biochem/physiol Actions

Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) serve as a bioactive lysophospholipid mediator. It favors mitogenic activity in quiescent fibroblasts. LPI has the ability to block hippocampal neuronal death in conditions of forebrain ischemia.

Packaging

2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-500ug)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

No data available

Flash Point(C)

No data available


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Julien Masquelier et al.
Journal of pharmaceutical and biomedical analysis, 126, 132-140 (2016-05-22)
Increasing evidence suggests that lysophosphatidylinositols (LPIs), a subspecies of lysophospholipids, are important endogenous mediators. Although LPIs long remained among the less studied lysophospholipids, the identification of GPR55 as their molecular target sparked a renewed interest in the study of these
Ann-Christin Otto et al.
Biochimica et biophysica acta. Molecular and cell biology of lipids, 1864(5), 662-676 (2019-02-09)
A defect of hepatic remodeling of phospholipids (PL) is seen in non-alcoholic fatty liver disease and steatohepatitis (NASH) indicating pivotal role of PL metabolism in this disease. The deletion of group VIA calcium-independent phospholipase A2 (iPla2β) protects ob/ob mice from
Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service